Holen Sie sich die Stockscreener-App
16.01
0.06%
-0.0308
Schlusskurs vom Vortag:
$16.04
Offen:
$15.98
24-Stunden-Volumen:
357.35K
Relative Volume:
0.23
Marktkapitalisierung:
$1.22B
Einnahmen:
$181.54M
Nettoeinkommen (Verlust:
$20.95M
KGV:
52.42
EPS:
0.3054
Netto-Cashflow:
$145.02M
1W Leistung:
-9.94%
1M Leistung:
-10.55%
6M Leistung:
+233.26%
1J Leistung:
+158.13%
1-Tages-Spanne:
$15.98
$16.62
1-Wochen-Bereich:
$15.70
$18.65
52-Wochen-Spanne:
$3.5001
$25.77
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Firmenname
Monte Rosa Therapeutics Inc
Sektor
Branche
Telefon
617-949-2643
Adresse
321 HARRISON AVENUE, BOSTON
Compare GLUE vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
16.03 | 1.22B | 181.54M | 20.95M | 145.02M | 0.3054 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.70 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.82 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
696.88 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.61 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.63 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | Eingeleitet | Wedbush | Outperform |
| 2023-01-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | Eingeleitet | UBS | Buy |
| 2022-08-15 | Eingeleitet | Jefferies | Buy |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-10-14 | Eingeleitet | SVB Leerink | Mkt Perform |
Alle ansehen
Monte Rosa Therapeutics Inc Aktie (GLUE) Neueste Nachrichten
Monte Rosa Therapeutics (GLUE) Likely to Surpass Earnings Forecasts: Will the Share Price Rise? - Bitget
Monte Rosa Therapeutics (GLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
Monte Rosa Therapeutics earnings on deck amid revenue decline - Investing.com
Assessing Monte Rosa Therapeutics (GLUE) Valuation After MRT-2359 Data Update And New Public Offering - Yahoo Finance
How Monte Rosa’s MRT-2359 Prostate Cancer Data and Funding Plans Could Shape GLUE’s Risk‑Reward Profile - Yahoo Finance
Is Monte Rosa Therapeutics Inc. stock attractive for income investors2026 Institutional Moves & Daily Growth Stock Tips - Naître et grandir
Profit Review: Will Monte Rosa Therapeutics Inc benefit from AI trendsJuly 2025 Breakouts & High Accuracy Trade Alerts - baoquankhu1.vn
What is Monte Rosa Therapeutics Incs market position2025 Momentum Check & Community Shared Stock Ideas - baoquankhu1.vn
Monte Rosa to focus on prostate cancer only for oncology asset MRT-2359 - MSN
Decliners Report: Is Monte Rosa Therapeutics Inc forming a bullish divergenceIPO Watch & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Dunn Edmund, principal accounting officer, sells Monte Rosa (GLUE) shares for $2496 - Investing.com India
Monte Rosa Therapeutics (NASDAQ:GLUE) CEO Markus Warmuth Sells 5,466 Shares - MarketBeat
Monte Rosa (GLUE) CEO Warmuth sells 5,466 shares under 10b5-1 plan - Stock Titan
GLUE (NASDAQ: GLUE) Rule 144 filing lists RSU vest and recent insider sales - Stock Titan
GLUE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Sees Significant Increase in Short Interest - MarketBeat
Monte Rosa Therapeutics (NASDAQ:GLUE) Insider Edmund Dunn Sells 25,164 Shares - MarketBeat
Edmund Dunn of Monte Rosa (GLUE) exercises options, sells 25,700 shares - Stock Titan
Markus Warmuth (GLUE) files Form 144 showing proposed sales and RSU dates - Stock Titan
Affiliate sale: GLUE (NASDAQ: GLUE) 536 shares via option exercise - Stock Titan
Monte Rosa Therapeutics CEO unveils pipeline progress at TD Cowen Health Care Conference - Traders Union
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
A Look At Monte Rosa Therapeutics (GLUE) Valuation After Positive MRT-2359 Clinical Data Update - simplywall.st
What Monte Rosa Therapeutics (GLUE)'s Phase 1/2 MRT-2359 Combo Data Means For Shareholders - Sahm
Monte Rosa Therapeutics advances MRT-2359 into Phase 2 trial targeting AR mutations in mCRPC - Traders Union
Insider Sell: Filip Janku Sells Shares of Monte Rosa Therapeutics Inc (GLUE) - GuruFocus
GLUEMonte Rosa Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Monte Rosa Therapeutics (GLUE) CMO sells 9,189 shares in open market - Stock Titan
Monte Rosa shares rise on prostate cancer trial results By Investing.com - Investing.com South Africa
Monte Rosa shares rise on prostate cancer trial results - Investing.com India
Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASC - The Manila Times
Filip Janku plans to sell 3,155 GLUE shares (NASDAQ: GLUE) - Stock Titan
Biotech firm Monte Rosa lines up three investor talks in March - Stock Titan
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - marketscreener.com
Does Monte Rosa Therapeutics Inc have pricing power2025 Buyback Activity & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Certain Restricted Stock Units of Monte Rosa Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-FEB-2026. - marketscreener.com
Certain Common Stock of Monte Rosa Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-FEB-2026. - marketscreener.com
What are Monte Rosa Therapeutics Inc.’s recent SEC filings showingWeekly Stock Recap & Stock Portfolio Risk Management - mfd.ru
Monte Rosa Therapeutics, Inc. $GLUE Shares Sold by GSA Capital Partners LLP - MarketBeat
Is Monte Rosa Therapeutics Inc. stock a top pick in earnings seasonAnalyst Downgrade & Weekly Momentum Picks - mfd.ru
BVF group discloses 5.9% Monte Rosa (NASDAQ: GLUE) ownership stake - Stock Titan
Portfolio Recap: Can Atomera Incorporated scale operations efficientlyEarnings Miss & Consistent Income Trade Ideas - baoquankhu1.vn
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Short Interest Update - MarketBeat
The Market Doesn't Like What It Sees From Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE) Revenues Yet As Shares Tumble 26% - simplywall.st
Does Monte Rosa Therapeutics Inc. have pricing power2025 Retail Activity & Free Community Consensus Stock Picks - mfd.ru
Is Monte Rosa Therapeutics Inc. forming a bullish divergenceWeekly Trade Summary & AI Based Buy/Sell Signal Reports - mfd.ru
Monte Rosa Therapeutics, Inc. Announces Executive Changes, Effective April 3, 2026 - marketscreener.com
Monte Rosa Therapeutics Announces Management Change - TradingView
Smart Money: How sensitive is Monte Rosa Therapeutics Inc to inflationEarnings Growth Report & Technical Buy Zone Confirmations - baoquankhu1.vn
3 High-Risk Stocks That Soared in 2025 But Can Still Fly Higher - Investing.com
Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE) institutional investors lost 12% last week but have benefitted from longer-term gains - Yahoo Finance
Finanzdaten der Monte Rosa Therapeutics Inc-Aktie (GLUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):